NCT05198609 2026-01-21
Camrelizumab, Apatinib Plus HAIC Versus Camrelizumab and Apatinib for HCC With Portal Vein Invasion: a Randomized Trial
Sun Yat-sen University
Phase 3 Active not recruiting
Clinical Trials
38 trialsNCT07314372 2026-01-20
FAD-HCC-001
The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School
Phase 2 Not yet recruiting
NCT04639180 2025-12-30
A Study to Evaluate Camrelizumab Plus Rivoceranib (Apatinib) as Adjuvant Therapy in Patients With Hepatocellular Carcinoma (HCC) at High Risk of Recurrence After Curative Resection or Ablation
Jiangsu HengRui Medicine Co., Ltd.
Phase 3 Active not recruiting
NCT07309419 2025-12-30
Cocktail-001
Shanghai Zhongshan Hospital
Phase 2/3 Not yet recruiting
NCT07157969 2025-12-01
ICIs and Anti-VEGF Antibody/TKIs With or Without Interventional Therapy for Advanced HCC
Peking Union Medical College Hospital
Phase 2 Recruiting
NCT06349317 2025-09-29
Neoadjuvant IMRT Combined With Camrelizumab and Apatinib for Resectable HCC With PVTT
Meng Chao Hepatobiliary Hospital of Fujian Medical University
Phase 2 Recruiting
NCT07192848 2025-09-25
Adebrelimab + Apatinib in Advanced HCC Post-Systemic Therapy
Cancer Hospital Chinese Academy of Medical Science, Shenzhen Center
Phase 2 Not yet recruiting
NCT06893887 2025-07-02
ICT-HCC
Nanjing Tianyinshan Hospital
Phase NA Recruiting
NCT04521153 2025-05-11
Camrelizumab Combined With Apatinib Mesylate for Perioperative Treatment of Resectable Hepatocellular Carcinoma
Shanghai Zhongshan Hospital
Phase 2/3 Active not recruiting
NCT06796803 2025-02-10
Camrelizumab Combined with Rivoceranib and Hepatic Arterial Infusion Chemotherapy (HAIC) As Conversion Therapy for Potentially Resectable Hepatocellular Carcinoma(HCC)
Shanghai Zhongshan Hospital
Phase 2/3 Not yet recruiting
NCT05613478 2024-12-31
Camrelizumab Combined With Apatinib Mesylate and TACE in the Perioperative Treatment of Hepatocellular Carcinoma
The First Affiliated Hospital with Nanjing Medical University
Phase 3 Recruiting
NCT06546280 2024-08-09
A Study of Camrelizumab Plus Apatinib as Adjuvant Therapy in Patients With Hepatocellular Carcinoma at High Risk of Recurrence After Radical Resection or Ablation
Zhujiang Hospital
Phase 2 Not yet recruiting
NCT06454578 2024-08-01
Adjuvant Adebrelimab Plus Apatinib for Participants With HCC at High-risk of Recurrence After Curative Resection
Qilu Hospital of Shandong University
Phase 2 Recruiting
NCT06482008 2024-07-01
HAIC Combined With Adebrelimab Plus Apatinib as the First-line Treatment for HCC in BCLC Stage C: An Open-label, Single-arm, Phase II Study
Sun Yat-sen University
Phase 2 Not yet recruiting
NCT06363825 2024-04-17
A Study of TAE+HAIC Combined With Camrelizumab and Apatinib in the Treatment of Advanced Hepatocellular Carcinoma
Fujian Medical University
Phase 2 Recruiting
NCT05924997 2024-02-21
Adebrelimab, Camrelizumab Plus Apatinib as First-line Therapy in Patients With Advanced Hepatocellular Carcinoma
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
Phase 1/2 Recruiting
NCT05062837 2024-01-23
Hepatectomy Combined With Camrelizumab and Apatinib in CNLC Stage IIIb HCC
Guangxi Medical University
Phase 2/3 Unknown
NCT02329860 2024-01-22
Study of Apatinib After Systemic Therapy in Patients With Hepatocellular Carcinoma(AHELP)
Jiangsu HengRui Medicine Co., Ltd.
Phase 3 Completed
NCT04559607 2023-12-18
TACE Combined With Camrelizumab and Apatinib in Intermediate and Advanced Hepatocelluar Carcinoma
Zhongda Hospital
Phase NA Unknown
NCT05099848 2023-08-15
A Trial of Conversion Treatment of HAIC Combined With Camrelizumab and Apatinib for Unresected Hepatocellular Carcinoma
Shandong Cancer Hospital and Institute
Phase 2 Unknown
NCT04930315 2023-06-13
CAPT
Zhejiang University
Phase 2 Unknown
NCT05171309 2021-12-28
Camrelizumab in Combination With Apatinib Plus NK Cell for Advanced HCC
Nanfang Hospital, Southern Medical University
Phase 2 Unknown
NCT04724226 2021-09-05
C-couple
Sun Yat-sen University
Phase 2 Unknown
NCT04665362 2021-01-22
IIT Study of M1-c6v1 Combined With SHR-1210 and Apatinib in Patients With HCC
Third Affiliated Hospital, Sun Yat-Sen University
Phase 1 Unknown
NCT04035876 2019-07-29
Combination Camrelizumab (SHR-1210) and Apatinib for Downstaging/Bridging of HCC Before Liver Transplant
Zhejiang University
Phase 1/2 Unknown
NCT04014101 2019-07-11
SHR-1210
Shanghai Zhongshan Hospital
Phase 2 Unknown
NCT03793725 2019-01-04
HZ-T-PD1-APA
Harbin Medical University
Phase 2 Unknown
NCT03722875 2018-12-19
SHR-1210 Plus Apatinib in Patients With Hepatocellular Carcinoma After Surgery
Shanghai Zhongshan Hospital
Phase NA Unknown
NCT03520257 2018-05-09
The Study of Apatinib Plus Radiotherapy vs. Apatinib in the Treatment of Hepatocellular Carcinoma With BCLC-C Stage I and Stage II Portal Vein Tumor Thrombus
Guangxi Medical University
Phase 2 Unknown
NCT03511703 2018-04-30
The Study of The Treatment of Postoperative Adjuvant Apatinib vs. TACE in Hepatocellular Carcinoma Patients
Guangxi Medical University
Phase 2 Unknown
NCT02942329 2018-02-26
Exploratory Clinical Study of Apatinib and SHR-1210 in Treating Advanced Hepatocellular Carcinoma or Gastric Cancer
The Affiliated Hospital of the Chinese Academy of Military Medical Sciences
Phase 1/2 Unknown
NCT03398122 2018-01-12
HCC
Tianjin Medical University Cancer Institute and Hospital
Phase NA Unknown
NCT03114085 2017-05-15
Apatinib Combined With Capecitabine Compared With Apatinib Treat Advanced Hepatocellular Carcinoma
First Affiliated Hospital of Guangxi Medical University
Phase 2 Unknown
NCT03066557 2017-02-28
Study of the Combination of TACE With Apatinib in Patients With Hepatocellular Carcinoma
Jiangsu Cancer Institute & Hospital
Phase NA Unknown
NCT03046979 2017-02-08
HCC
Tianjin Medical University Cancer Institute and Hospital
Phase 2 Unknown
NCT02772029 2016-05-13
A Study of Apatinib for Advanced Hepatocellular Carcinoma Patients After First-line Treatment Failure
The First Affiliated Hospital of Zhengzhou University
Phase 1/2 Unknown
NCT02727309 2016-04-04
A Study of Second-line Treatment With Apatinib After TACE in Advanced Hepatocellular Carcinoma Patients
Peking University Cancer Hospital & Institute
Phase 1/2 Unknown
NCT02702323 2016-03-08
Treatment Patients With Pulmonary Metastasis of Liver Cancer With Apatinib Combination With TACE: a Clinical Study
Zhejiang Cancer Hospital
Phase 2/3 Unknown